RedChip Companies, Inc.: Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money Show on CNBC and Bloomberg TV
RedChip Companies says it will air interviews on Bloomberg TV and CNBC featuring Virax Biolabs Group Ltd. (Nasdaq:VRAX) and Transcode Therapeutics Inc. (Nasdaq:RNAZ). Virax CEO James Foster discusses post-fiscal 2026 balance sheet and Nasdaq bid compliance, plus ImmuneSelect supply talks. Transcode CEO Philippe Calais covers TTX-MC138 Phase 2a progress in ctDNA+ colorectal cancer.
How this was made
The 30-second read
Why it matters
The article’s tradable content is the disclosed clinical milestone for RNAZ (Phase 2a advancement) and the disclosed commercialization/compliance updates for VRAX (Nasdaq bid-price compliance regained and a supply agreement with Fosun Diagnostics). However, it does not provide new financial results or additional trial efficacy data beyond what is described.
Market read
Traders may use the disclosed milestones to gauge near-term sentiment and catalyst calendars, but the format (TV interview promotion) reduces immediacy versus filings or new trial data.
What to watch
The text lacks hard financial metrics, enrollment numbers, or efficacy readouts for the Phase 2a program, so the market may focus on execution risk and timeline uncertainty rather than the milestone headline.
Background
RedChip Companies is promoting TV interviews with two Nasdaq-listed biotech companies, summarizing recent business and clinical progress.
Ticker impact
Virax CEO discusses fiscal 2026 positioning, Nasdaq bid-price compliance, and progress across ViraxImmune and ImmuneSelect, including a new Fosun Diagnostics supply agreement.
Moderate upside bias if investors view the Fosun Diagnostics deal as credible commercialization traction; otherwise limited impact given it is an interview/IR broadcast.
The article contains concrete business updates (Nasdaq compliance regained, supply agreement details, clinical/commercial next steps) but does not provide new trial readouts or financial numbers, and it is framed as an interview airing on TV.
TransCode CEO highlights TTX-MC138 advancing into Phase 2a for ctDNA-positive colorectal cancer after Phase 1a safety and tolerability results.
Potential positive reaction, especially among traders focused on oncology pipeline milestones, though magnitude may be tempered by the lack of new efficacy data in this text.
The article discloses a specific clinical-stage milestone (Phase 2a initiation) and prior Phase 1a safety/tolerability outcomes, which are decision-relevant, but it is still a promotional interview announcement without fresh quantitative efficacy endpoints.
Market effects
Reinforces small-cap biotech attention on immune profiling diagnostics (VRAX) and ctDNA-guided oncology development (RNAZ), but no sector-wide regulatory or funding shift is disclosed.
Mentions Southeast Asia markets in the Fosun Diagnostics supply agreement, which could marginally support regional commercialization expectations for VRAX.
Limited global impact beyond the companies’ own commercialization and clinical development narratives.
Counterpoint
Because this is an interview/IR broadcast, traders may discount it versus primary-source catalysts like SEC filings, trial results, or financing updates; price moves may fade quickly.
Key entities
- companyVirax Biolabs Group Ltd.
Nasdaq-listed biotech focused on immune response detection and T cell immune profiling; updates include ImmuneSelect commercialization strategy and a Fosun Diagnostics supply agreement.
- companyTransCode Therapeutics Inc.
Nasdaq-listed immuno-oncology company; updates include TTX-MC138 moving into Phase 2a for ctDNA-positive colorectal cancer after Phase 1a safety/tolerability results.
- companyRedChip Companies
Investor relations and media firm running the Small Stocks, Big Money show on Bloomberg TV and CNBC.
